Leads Biolabs Secures Priority Review for Opamtistomig
NANJING, China | July 10, 2026 Nanjing Leads Biolabs Co., Ltd. has announced that the Center for Drug Evaluation...
PD-L1
Advertisement
Merck and Gilead End KEYNOTE-D46 Study Update
RAHWAY, N.J. and FOSTER CITY, Calif., June 8, 2026 Merck (NYSE: MRK) and Gilead Sciences (Nasdaq: GILD) announced the...
Leads Biolabs’ Opamtistomig Shows Strong NSCLC Response Ahead of WCLC 2026
NANJING, China, May 28, 2026 Nanjing-based Leads Biolabs announced that updated Phase II clinical data for its proprietary PD-L1/4-1BB...
BeOne Medicines Reports Positive Phase 3 HERIZON-GEA Results at ASCO 2026
CHICAGO, Illinois and SAN CARLOS, California — May 27, 2026 BeOne Medicines announced new clinical findings from the Phase...
Leads Biolabs Wins Phase III Approval for Opamtistomig in Advanced EP-NEC
NANJING, China, May 18, 2026 Leads Biolabs announced that its proprietary PD-L1/4-1BB bispecific antibody Opamtistomig (LBL-024) has received approval...
Advertisements
Merck Wins EU Approval for KEYTRUDA Combo in Ovarian Cancer
RAHWAY, N.J., April 2, 2026 Merck (MSD) has secured a major regulatory milestone as the European Commission approves KEYTRUDA®...
Advertisement
